National ICMR Distances Itself From BHU's 'Poorly Designed' Study On Covaxin Side Effects BY Asmita Ravi Shankar
International AstraZeneca's Covid-19 Vaccine Can Cause A Second 'Rare' Blood Clotting Disorder? | What Research Says BY Jheelum Basu
International AstraZeneca Rolls Back Covid-19 Vaccine Amid Row Over Side- Effects, Terms It 'Purely Coincidental' BY Outlook Web Desk
National Bharat Biotech Highlights Covaxin's 'Safety First' Feature Amid AstraZeneca's Covishield Row Over Side Effects BY Outlook Web Desk
National PM Modi's Pic Disappears From CoWIN Certificates Amid Covishield Side Effects Row; Health Ministry Responds BY Outlook Web Desk
International 'Sympathy To Those Who Lost Loved Ones': AstraZeneca On Covishield Side Effects BY Outlook Web Desk
National 'Who Would Be Responsible For Heart Attack Deaths': Oppn Parties Slam BJP Over Covishield Row BY PTI
International Covishield Maker AstraZeneca Admits Its Covid Vaccine Can Cause Rare Side Effects BY Outlook Web Desk
National Serum Institute Seeks Inclusion Of Covovax On CoWIN As Heterologous Booster Dose For Adults BY PTI
National Covovax Booster Dose For Covid-19, Its Efficacy Rate And How Does It Work? All You Need To Know BY Outlook Web Desk
National SII's Free Supply Of Covishield To Centre: First Lot Of 80 Lakh Doses Set For Dispatch BY PTI
National Corbevax As Booster Maximises Protection In Covishield Vaccinated People: AIG Hospitals Study BY PTI
National Government Not Liable For Vaccine-Related Deaths: Centre To Supreme Court BY Outlook Web Desk
National Telangana Asks Centre To Supply 50 Lakh Doses Of Covishield To Ramp Up Booster Jabs BY Outlook Web Desk
National Immunity From Natural Covid Infection, Vaccines Not Absolute: Minister of State for Health BY Outlook Web Desk
National Biological E Seeks EUA For Corbevax As Booster In Adults Vaccinated With Covishield, Covaxin BY Outlook Web Desk
National SII To Give Free Covishield Vials To Pvt Vaccination Centres To Compensate For Price Difference BY Outlook Web Desk
National Second Covishield Dose Can Be Given Between 8-16 Weeks After First Dose, Says NTAGI Reducing Gap BY Outlook Web Desk
National Covishield And Covaxin Get Regular Market Approval For Use In Adult Population BY Outlook Web Desk
National Regular Market Approval Likely To Cap Covishield, Covaxin Price At Rs 275 BY Outlook Web Desk
